Indications
Metazine MR is prescribed for adults as an adjunctive therapy to manage stable angina pectoris when first-line antianginal treatments are ineffective or intolerable.
Pharmacology
Trimetazidine Dihydrochloride is a unique 3-keto acyl CoA thiolase inhibitor, which helps in treating coronary artery disease. It works by shifting the heart’s energy production from fatty acids to glucose, a more efficient energy source. This shift reduces lactic acid build-up, thus preventing angina pectoris.
Dosage & Administration
The standard dose is 35 mg twice daily or 20 mg three times daily with meals. Evaluate the treatment’s effectiveness after three months; discontinue if no benefit is observed.
Interaction
No significant interactions have been reported with other common medications, including beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents, or digitalis preparations.
Contraindications
Avoid use in patients with hypersensitivity to trimetazidine or any excipients, as well as those with Parkinson’s disease, parkinsonian symptoms, tremors, restless legs, or severe renal impairment.
Side Effects
Generally well-tolerated, but possible side effects include dizziness, headache, abdominal pain, diarrhea, dyspepsia, nausea, vomiting, rash, pruritus, urticaria, and asthenia.
Pregnancy & Lactation
Limited data is available on the use of trimetazidine during pregnancy. As a precaution, it should be avoided. Safety during breastfeeding is not established, so it is advised against use during lactation.
Precautions & Warnings
Metazine MR should not be used to treat acute angina attacks, unstable angina pectoris, or myocardial infarction.
Therapeutic Class
Other Anti-anginal & Anti-ischaemic Drugs
Storage Conditions
Store in a dry place, away from light and heat. Keep out of reach of children.
Reviews
There are no reviews yet.